No headlines found.
No press releases found.
No news found.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.
Check-Cap Ltd. - Ordinary Share trades on the NASDAQ stock market under the symbol CHEK.
As of September 27, 2024, CHEK stock price declined to $1.17 with 58,473 million shares trading.
CHEK has a market cap of $6.87 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, CHEK traded as high as $26.20 and as low as $1.13.
CHEK has underperformed the market in the last year with a price return of -73.9% while the SPY ETF gained +35.8%. CHEK has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -40.1% and -34.4%, respectively, while the SPY returned +4.9% and +2.0%, respectively.
CHEK support price is $1.28 and resistance is $1.42 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CHEK shares will trade within this expected range on the day.